Clinical trial
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated…
NCT00246571 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00246571 |
|---|---|
| Title | Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer |
| Official title | A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | SU011248, Chemotherapy |
| Enrollment | 217 |
| Start date | Jan 1, 2006 |
| Primary completion | May 1, 2010 |
| Completion | Jun 1, 2011 |
| First posted | Oct 31, 2005 |
| Last update posted | Jul 12, 2012 |
| Countries | Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, Spain, Turkey (Türkiye), Ukraine, United Kingdom, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: